Head to Head Contrast: Portage Biotech (NASDAQ:ALP) vs. Soluna (NASDAQ:SLNH)

Soluna (NASDAQ:SLNH) and Portage Biotech (NASDAQ:ALP) are both small-cap technology companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Profitability

This table compares Soluna and Portage Biotech’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Soluna	-182.16%	-52.19%	-32.17%
Portage Biotech	N/A	N/A	N/A

Earnings and Valuation

This table compares Soluna and Portage Biotech”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Soluna	$29.72 million	9.75	-$53.41 million	($1.12)	-1.05
Portage Biotech	$100,000.00	22.98	-$38.63 million	($8.18)	-0.01

Portage Biotech has lower revenue, but higher earnings than Soluna. Soluna is trading at a lower price-to-earnings ratio than Portage Biotech, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Soluna has a beta of 5.07, suggesting that its share price is 407% more volatile than the S&P 500. Comparatively, Portage Biotech has a beta of 0.54, suggesting that its share price is 46% less volatile than the S&P 500.

Insider & Institutional Ownership

23.2% of Soluna shares are held by institutional investors. Comparatively, 13.4% of Portage Biotech shares are held by institutional investors. 15.5% of Soluna shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings and price targets for Soluna and Portage Biotech, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Soluna	1	1	1	0	2.00
Portage Biotech	1	2	0	0	1.67

Soluna presently has a consensus price target of $4.00, indicating a potential upside of 240.43%. Portage Biotech has a consensus price target of $0.25, indicating a potential upside of 155.36%. Given Soluna’s stronger consensus rating and higher probable upside, equities research analysts plainly believe Soluna is more favorable than Portage Biotech.

Summary

Soluna beats Portage Biotech on 8 of the 14 factors compared between the two stocks.

About Soluna

Soluna Holdings, Inc. together with its subsidiaries, engages in the mining of cryptocurrency through data centers. It operates through two segments, Cryptocurrency Mining and Data Center Hosting. The company also operates in the blockchain business. In addition, the company develops and builds modular data centers that use for cryptocurrency mining. Further, it provides data center hosting services, including electrical power and network connectivity to cryptocurrency mining customers. The company was formerly known as Mechanical Technology Inc and as changed to Soluna Holdings, Inc. Soluna Holdings, Inc. was incorporated in 1961 and is headquartered in Albany, New York.

About Portage Biotech

Portage Biotech Inc., together with its subsidiaries, researches and develops pharmaceutical and biotechnology products. The company’s product includes IMM60, an iNKT cell activator; IMM65, a PLGA-nanoparticle combined with a NY-ESO-1 peptide vaccine; INT230-6 that is in Phase I/II clinical trials for the treatment of solid tumors; STING, a small molecule that binds to the stimulator of interferon genes in cancer; CellPorter, a cell permeable peptide platform technology derived from human proteins; PPL-003, an ophthalmic solution; and SBI-101, a blood-conditioning technology to restore balance to the immune system after acute vital organ injury, such as acute kidney injury. It also focuses on nanolipogel technology for use in immune-oncology; and antibodies against a novel T-cell for use as a monotherapy and combination therapy for solid and haematological malignancies. In addition, the company develops antibodies implicated in the inflammatory tumor and tumor-infiltrating immune cell microenvironments; and FOXO4-P53 modulator and C-RAF inhibitor. Portage Biotech Inc. is based in Tortola, British Virgin Islands.